Psychiatry's Medication Pipeline in Motion.

The article provides updates on medications used for psychiatric conditions. These include N-methyl-D-aspartate (NMDA)-glutamate antagonism/Sigma-1 agonism for agitation in dementia, as well as norepinephrine, dopamine and serotonin reuptake inhibitors for the treatment of attention-deficit/hyperact...

Descripción completa

Detalles Bibliográficos
Publicado en:	Psychiatric Times Vol. 43; no. 5; pp. 6 - 10
Autor principal:	Miller, John J.
Formato:	Artículo
Publicado:	MJH Life Sciences May2026
Materias:	United States. Food & Drug Administration Mental illness drug therapy Attention-deficit hyperactivity disorder Agitation (Psychology) Hallucinogenic drugs Medical research Mental depression Drug therapy for schizophrenia Investigational drugs Antipsychotic agents Drug approval Drug development Dementia Cholinergic receptors Disease complications
Acceso en línea:	Ver este registro en EBSCOhost

Descripción
Sumario:	The article provides updates on medications used for psychiatric conditions. These include N-methyl-D-aspartate (NMDA)-glutamate antagonism/Sigma-1 agonism for agitation in dementia, as well as norepinephrine, dopamine and serotonin reuptake inhibitors for the treatment of attention-deficit/hyperactivity disorder (ADHD), and opioid K receptor antagonism and α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor potentiator for major depressive disorder.